Other medicines used in cancer

The Oncology Online Quality System (OOQS) provides up-to-date quality-controlled Edinburgh Cancer Centre documentation, including Clinical Management Guidelines by tumour group, SACT lists and procedures. OOQS includes guidelines for managing conditions associated with malignancy and treatment related side-effects.

This section includes cancers that are not included in any of the other nine tumour types and may be of the following cancer types: Glioblastoma; Thyroid cancers; Glioma; Skeletal/bone cancers; Neuroblastoma; Solid tumours; Sarcoma; Neuroendocrine tumours; Mesothelioma; Adrenal cancers; Osteosarcoma. See formulary recommendations for treatment of neuroendocrine tumours.

This section also includes medicines used for conditions associated with malignancy and for the treatment of side-effects associated with SACT.

A list of all formulary decisions relating to other medicines used in cancer can be viewed the Formulary Decisions section of the website. Formulary decisions are agreed through SCAN and across all three Boards.

See also Scottish Sarcoma Network guidelines.

OOQS: Tumour Site (intranet) OOQS: Systemic Anticancer Therapy (intranet) OOQS: SACT or SACT Toxicity (intranet) OOQS: Cancer Complications (intranet)